ArticleFrontiers in immunology2026
Myeloid-derived PD-L1 characterizes spatially organized immune architecture in colorectal cancer.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- CXCL11 recruits immunosuppressive cells to form a barrier at the invasive front of pancreatic cancer by activating the NF-κB/CCL2 axis.Translational oncology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The tumor immune microenvironment (TIME) is highly heterogeneous and strongly influences immunotherapy outcomes and patient prognosis in colorectal cancer (CRC). In this exploratory study, we used three multiplex immunofluorescence (mIF) assays to characterize the spatial immune microenvironment associated with high CD8/PD-L1 infiltration. Methods: Three mIF assays quantified the cell densities (cells/mm Results: PD-L1 expression was predominantly driven from stromal and immune cells with enrichment at IM versus TC, particularly on CD163 Conclusions: This exploratory mIF analysis identifies PD-L1 expression predominantly on stromal and immune cells, enriched in IM, particularly on CD163
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.